Allows a licensed pharmacist to prescribe and order FDA-approved medication assisted therapy under a non-patient-specific regimen for the treatment of opioid use disease.
Requires hospitals to have a registered professional nurse as a sitting and voting member of the governing entity responsible for developing a hospital's strategic plan, structure, systems, policies and programs.
Requires the administration of certain vaccines for children in accordance with regulations issued by the commissioner, utilizing generally accepted medical standards and based on recommendations of the American Academy of Pediatrics, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, the American College of Physicians, the Advisory Committee on Immunization Practices, or other similar nationally or internationally recognized scientific organizations.
Relates to the establishment of regulations for administering immunizations taking into consideration the recommendations of the American Academy of Pediatrics, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, the American College of Physicians, the advisory committee on immunization practices, any interstate body established for purposes of reviewing and making recommendations regarding immunization coverage and access, or other similar nationally or internationally recognized scientific organizations.
This bill requires health insurance plans to reimburse providers for all costs associated with administering recommended vaccinations, including both vaccine acquisition costs (based on CDC private sector rates plus 21% for shipping/storage) and full administration costs (like counseling, supplies, and nursing time, using current Medicare rates). It directly affects healthcare providers (such as clinics and doctors' offices) who administer vaccines, ensuring they are compensated for the full cost of delivery. The reimbursement applies specifically to vaccines recommended by the CDC's immunization practices committee, covering standard childhood and adult vaccines like measles, polio, and flu shots. This policy change aims to remove financial barriers for providers to offer routine vaccinations under insurance coverage.
S 8334 requires health insurance plans to cover all recommended doses of the COVID-19 vaccine (SARS-CoV-2), adding it to a list of mandatory immunizations already covered by New York insurance law. This affects insurance companies, healthcare providers, and patients by mandating reimbursement for the vaccine without cost-sharing. The bill amends multiple sections of New York’s insurance and social services laws to include "severe acute respiratory syndrome coronavirus 2" in required coverage, aligning with federal standards for biological products. It applies to all insurance contracts effective January 1 after the law takes effect.
Enacts the "New York affordable drug manufacturing act" to direct the commissioner of health to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs.
Provides funding for abortion services and travel-related expenses not covered by the military for active duty members of the armed forces of the United States, or their spouses or dependents, who are New York state residents.
Relates to the use of antipsychotic medications in nursing homes; imposes limits as to time and documentation; requires informed consent under certain circumstances.
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.
